
    
      The primary objective of this study is to show that ATLAS Therapy, (L-Arginine;
      Tetrahydrobiopterin; L-Ascorbate) is bioavailable in humans and exerts a measurable effect on
      its in vivo biological signature, Flow Mediated Vasodilation (FMD) in people with
      intermittent claudication caused by peripheral arterial disease. This will be a Phase I /
      dose finding study. All subjects will receive 2 different drug doses of the Kuvan the first
      45 days they will receive 10 mg/kg/day. The second 45 days they will receive 20/mg/kg/day.
    
  